Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Aug 23, 2012 (14 years ago)

Novarel¿ (Chorionic Gonadotropin for injection, USP)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Labeling; incorrect or missing insert; Warnings portion of the Package Insert is missing the warning statement: Anaphylaxis has been reported with urinary-derived hCG products.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Novarel¿ (Chorionic Gonadotropin for injection, USP), 10,000 USP FOR INTRAMUSCULAR USE ONLY Rx Only NDC 55566-1501-0 Manufactured for : Ferring Pharmaceuticals Inc., Parsippany, NJ 07054 Manufactured by: DRAXIS Specialty Pharmaceuticals Inc., Quebec, Canada. NDC # 55566-1501-0 is assigned to the vial of NOVAREL and is displayed on the vial label. NDC # 55566-1501-1 is assigned to the unit of sale, which is a carton containing 1 vial of NOVAREL and 1 vial of diluent along with the insert. NDC # 55566-1501-1 is displayed on the unit of sale and is the item subject to recall.

Affected NDCs 55566-1501-00 55566-1501-01

Compare with the code on your package — it is the most precise check available.

Recalling firm
Ferring Pharmaceuticals Inc
NDC code
55566-1501-0
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-073-2013 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Ferring Pharmaceuticals Inc

All 2012 recalls
Class II · Moderate risk

Endometrin

cGMP deviations: potential for Microbial Contamination of Non-Sterile Products

Terminated Microbial contamination Ferring Pharmaceuticals Inc NDC 55566-6500-03 D-0879-2023
Class II · Moderate risk

ZOMA-Jet 10 Demonstration Kit

Defective Delivery System: customer complaints concerning the injector pen breaking apart and disintegrating into pieces.

Terminated Packaging defect Ferring Pharmaceuticals Inc D-0318-2021
Class II · Moderate risk

ZOMA-Jet 5 Demonstration Kit

Defective Delivery System: customer complaints concerning the injector pen breaking apart and disintegrating into pieces.

Terminated Packaging defect Ferring Pharmaceuticals Inc D-0317-2021
Class III · Low risk

Menopur 75 IU

Failed pH specifications: Out of Specification pH results for 0.9% Sodium Chloride, USP

Terminated Failed specification Ferring Pharmaceuticals Inc NDC 55566-7501-2 D-0299-2021

Other labeling / mix-up recalls from 2012

All labeling / mix-up recalls
Class III · Low risk

Divalproex Sodium Delayed-Release Tablets

Labeling: Label Error On Declared Strength; Some bottles of product were missing the color-coded strength on the primary display panel of the label.

Terminated Labeling / mix-up Upsher Smith Laboratories, Inc. NDC 0245-0182-11 D-127-2013
Class III · Low risk

Bronkaid Dual Action Formula

Labeling: Label lacks warning or Rx legend; Certain information was inadvertently excluded from the product carton label.

Terminated Labeling / mix-up Bayer Healthcare, LLC D-177-2013
Class II · Moderate risk

Synthroid (Levothyroxine Sodium)

Labeling: Error on Declared Strength. Product labeled to contain 150 mcg tablets actually contained 75 mcg tablets.

Terminated Labeling / mix-up Abbott Laboratories NDC 0074-7069-90 D-107-2013